期刊文献+

原发性骨髓纤维化的治疗进展 被引量:5

下载PDF
导出
摘要 原发性骨髓纤维化(PMF)是一种不常见的造血干细胞克隆性增殖性疾病(MPN),以骨髓纤维组织增生并髓外造血为特点,出现进行性贫血、脾脏肿大,伴有发热、乏力、盗汗、消瘦等全身症状。在MPN中生存期和生活质量都是最差的,中位生存期约5年,最终将进展为骨髓衰竭或转化为急性白血病。近年来低强度预处理的造血干细胞移植和靶向药物等已经用于PMF的治疗并初显疗效,现将PMF治疗进展作一综述。
出处 《疑难病杂志》 CAS 2014年第5期542-545,共4页 Chinese Journal of Difficult and Complicated Cases
基金 重庆市卫生局重点项目(No.2011-1-032)
  • 相关文献

参考文献6

二级参考文献43

  • 1张瑾,胡彩华.成人急性淋巴细胞白血病骨髓活检与疾病预后的关系[J].临床荟萃,2006,21(22):1624-1626. 被引量:1
  • 2张之南.血液病诊断及疗效标准(第二版)[M].北京:科学出版社,1999.271-272. 被引量:11
  • 3沈迪 王辨明 等.临床血液学(第一版)[M].北京:人民卫生出版社,1991.657. 被引量:1
  • 4Jones AV; Kreil S, Zoi K, et al. Widespread aceuranee of the JAK2 V617F mutation in chronic myeloproliferative disorders [ J ]. Blood, 2005, 106 ( 6 ) : 2 162-2 168. 被引量:1
  • 5Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythenfia vera[J]. J Biol Chem, 2005,280 (24) : 22 788-22 792. 被引量:1
  • 6Kralovies R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2[ J]. Blood,2005,106(10) :3 374- 3 376. 被引量:1
  • 7Yet ST, Me Anulty MM, Foha SC, et al, Human EZF, a kruppel-like zinc finger protein,is expressed in vascular endothelial cells and contains transcriptional activation and repression domains [ J ]. J Biol chem, 1998, 273 ( 2 ) : 1 026-1 031. 被引量:1
  • 8Windy BF, Melanie J. MeConnell RT, The Transcriptional Profile of PV Displays Limited Similarity to EPO Stimulated Progenitor Cells: Evidence That JAK2 V617F Confers a Novel Program to Malignant Hematopoietic Stero Cells [C]. Blood (ASH Annual Meeting Abstracts)2005,106: Abstract 120. 被引量:1
  • 9Manoharan A.Myelofibrosis:Prognostic factors and treatment[J].Br J Haematol,1988,69(3):295-298. 被引量:1
  • 10浦权,杨梅如.血液病骨髓病理手册[M].北京:科学出版社,2003;7. 被引量:1

共引文献20

同被引文献45

  • 1赖洵,闻艳,张爱玲,杨同华,李正发,陆智祥.沙利度胺联合促红细胞生成素治疗原发性骨髓纤维化疗效观察[J].中国医师杂志,2006,8(5):709-709. 被引量:1
  • 2黄韬,仇登波.脾脏的生理功能及其临床应用[J].腹部外科,1996,9(4):162-164. 被引量:13
  • 3Campbell PJ, Green AR. The myeloproliferative disorders[J]. N EngJ Med, 2006,355 (24) : 2452- 2466. 被引量:1
  • 4Levine RL, Gilliland DC. Myeloproliferative disorders[J]. Blood,2008,112(6):2190-2198. 被引量:1
  • 5Pikman Y,Lee BH,Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia[J]. PLoS Med,2006,3(7) :e270. 被引量:1
  • 6Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms[J]. EnglJ Med,2013,369(25):2379-2390. 被引量:1
  • 7NangaliaJ, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutatedJAK2[J]. N EnglJ Med,2013,369(25):2391-2405. 被引量:1
  • 8Tefferi A,Lasho TL,et al. CALR vsJAK2 vs MPL-mutated or triple -negative myelofibrosis: clinical, cytogenetic and molecular comparisons[J]. Leukemia, 2014 , 28 (7): 1472- 1477. 被引量:1
  • 9Rumi E,Pietra D,ferretti V ,et al.JAK2 orCALR mutation status defines of essential thromboeythemia with substantially Different clinical course and outcomes[J]. Blood,2014, 123 (10): 1544-1551. 被引量:1
  • 10ChiJ, Nicolaidou V, Nicolaidou V, et al. Calreticulin exon 9 frameshift mutations in patients with thrombocytosis[J]. Leukemia,2013,28(5): 1152-1154. 被引量:1

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部